Form 4 for TVTX Travere Therapeutics, Inc.
Accepted 2026-04-16 16:05:15 ET · period of report 2026-04-14 · accession 0001680739-26-000005 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DMT | 2026-04-16 16:05 | 2026-04-14 | TVTX | Baynes Roy D. | Dir | M - OptEx | $17.60 | +32.8K | 70.2K | +87% | +$576.3K |
| DMT | 2026-04-16 16:05 | 2026-04-14 | TVTX | Baynes Roy D. | Dir | S - Sale+OE | $41.29 | -32.8K | 37.5K | -47% | -$1.35M |
| DMT | 2026-04-16 16:05 | 2026-04-14 | TVTX | Baynes Roy D. | Dir | M - OptEx | $0.00 | -32.8K | 6,750 | -83% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-04-14 | M | A | 8,000 | $17.94 | 45,500 | D | — | — | |
| 2 | Common | Common Stock | 2026-04-14 | M | A | 9,000 | $15.43 | 54,500 | D | — | — | |
| 3 | Common | Common Stock | 2026-04-14 | M | A | 4,500 | $18.27 | 59,000 | D | — | — | |
| 4 | Common | Common Stock | 2026-04-14 | M | A | 4,500 | $21.38 | 63,500 | D | — | — | |
| 5 | Common | Common Stock | 2026-04-14 | M | A | 6,750 | $17.11 | 70,250 | D | — | — | |
| 6 | Common | Common Stock | 2026-04-14 | S | D | 26,000 | $41.07 | 44,250 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. |
| 7 | Common | Common Stock | 2026-04-14 | S | D | 6,750 | $42.12 | 37,500 | D | — | — | (F1) This sale was made pursuant to a written plan adopted on November 17, 2025, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and consists of the sale of shares underlying stock options granted to the Reporting Person. |
| 8 | Derivative | Stock option (right to buy) | 2026-04-14 | M | D | 8,000 | $0.00 | 0 | D | $17.94 · — to 2029-05-08 | 8,000 Common Stock | (F2) The stock option is fully vested and exercisable. |
| 9 | Derivative | Stock option (right to buy) | 2026-04-14 | M | D | 9,000 | $0.00 | 0 | D | $15.43 · — to 2030-05-15 | 9,000 Common Stock | (F2) The stock option is fully vested and exercisable. |
| 10 | Derivative | Stock option (right to buy) | 2026-04-14 | M | D | 4,500 | $0.00 | 4,500 | D | $18.27 · — to 2031-05-14 | 4,500 Common Stock | (F2) The stock option is fully vested and exercisable. |
| 11 | Derivative | Stock option (right to buy) | 2026-04-14 | M | D | 4,500 | $0.00 | 4,500 | D | $21.38 · — to 2032-05-11 | 4,500 Common Stock | (F2) The stock option is fully vested and exercisable. |
| 12 | Derivative | Stock option (right to buy) | 2026-04-14 | M | D | 6,750 | $0.00 | 6,750 | D | $17.11 · — to 2033-05-17 | 6,750 Common Stock | (F2) The stock option is fully vested and exercisable. |